Abstract
Background
Cervical and endometrial carcinoma incidentally found in the surgical specimen with high risk pathological finding or with gross residual disease.
Material and Methods
Between 2004 and 2010, 320 cervical and endometrial cancer patients were treated with EBRT and brachytherapy after having undergone total/subtotal hysterectomy. Sixty patients were lost to follow-up.
Results
Median follow-up was 21 months. Endometrial and cervical cancer with a high risk for local recurrence achieved CR 93.8 and 89 %, respectively. 56 % patients experienced CR with residual disease with cervical cancer. Median OS for endometrial and cervical cancer with residual disease was 8.5 and 24 months, respectively. Grade 3 adverse events were 5 and 3.5 % for rectum and bladder, respectively.
Conclusion
The incorporation of chemotherapy during pelvic radiotherapy followed by HDR interstitial brachytherapy for residual disease is inadequate and improves survival. We are still in learning phase of brachytherapy in post-operative gynaecological malignancy cases; expertise will be developed by practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen SW, Liang JA, Yang SN. Postoperative radiotherapy for patients with invasive cervical cancer following treatment with simple hysterectomy. Jpn J Clin Oncol. 2003;33(9):477–81.
Jolly S, Vargas C, Kumar T. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol. 2005;97(3):887–92.
Igboeli P, Kapp DS, Lawrence R. Carcinoma of the cervical stump: comparison of radiation therapy factors, survival and patterns of failure with carcinoma of the intact uterus. Int J Radiat Oncol Biol Phys. 1983;9(2):153–9.
Das RK, Patel R, Shah H. 3D CT-based high-dose-rate breast brachytherapy implants: treatment planning and quality assurance. Int J Radiat Oncol Biol Phys. 2004;59(4):1224.
Nandwani PK, Vyas RK, Neema JP. Retrospective analysis of role of interstitial brachytherapy using template (MUPIT) in locally advanced gynecological malignancies. J Cancer Res Ther. 2007;3(2):111–5.
Liu MT, Hsu JC, Liu WS. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Eur J Cancer Care (Engl). 2008;17(2):174–81.
Hart K, Han I, Deppe G. Postoperative radiation for cervical cancer with pathologic risk factors. Int J Radiat Oncol Biol Phys. 1997;37(4):833–8.
Perkins PL, Chu AM, Jose B. Posthysterectomy megavoltage irradiation in the treatment of cervical carcinoma. Gynecol Oncol. 1984;17(3):340–8.
Ampil F, Datta R, Datta S. Elective postoperative external radiotherapy after hysterectomy in early-stage carcinoma of the cervix. Is additional vaginal cuff irradiation necessary? Cancer. 1987;60(3):280–8.
Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62(740):679–94.
Smith HO, Qualls CR, Romero AA. Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix? Gynecol Oncol. 2002;85(2):229–41.
Schorge JO, Lee KR, Flynn CE. Stage IA1 cervical adenocarcinoma: definition and treatment. Obstet Gynecol. 1999;93(2):219–22.
Scholten AN, van Putten WL, Beerman H. PORTEC Study Group. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63(3):834–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sau, S., Ghosh, S., Mitra, S. et al. A Retrospective Six Years Analysis of Survival and Late Morbidity of Post-operative Gynaecological Malignancy Treated with External Radiotherapy Followed by Brachytherapy in Medical College & Hospitals, Kolkata. J Obstet Gynecol India 63, 128–134 (2013). https://doi.org/10.1007/s13224-012-0246-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13224-012-0246-5